The association between antibiotic use and outcomes of HCC patients treated with immune checkpoint inhibitors.

ABSTRACT:

Objective

Recently, immune checkpoint inhibitor (ICI) treatment has shown encouraging performance in improving the prognosis of hepatocellular carcinoma (HCC) patients. The gut microbiome plays a vital role in altering the efficacy of ICIs, which may be impacted by antibiotics. The aim of the meta-analysis is to estimate the influence of antibiotic use on the survival of HCC patients treated with ICIs.

Methods

The literature review was conducted using databases like PubMed, EMBASE, Cochrane Library, CNKI, WANFANG DATA, VIP, Google Scholar, and ClinicalTrials.gov before May 15, 2022. The primary endpoints were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR).

Results

A total of six retrospective studi

SUBMITTER: Zhang L 

PROVIDER: S-EPMC9429218 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature